5.3 Investigational Product Investigator's Brochure (IB)

The Investigator’s Brochure (IB) is one of the most critical documents in any clinical trial. While the protocol tells the research team what to do and how to do it, the IB tells the team why they are doing it and what to expect regarding the investigational product.

Definition and Purpose

According to ICH GCP, the Investigator’s Brochure is a compilation of the clinical and nonclinical data on the investigational product(s) (IP) that is relevant to the study of the investigational product in human subjects.

The primary purpose of the IB is to provide the investigators, trial site staff, and the Institutional Review Board/Independent Ethics Committee (IRB/IEC) with the information necessary to facilitate an understanding of the rationale for, and compliance with, many key features of the protocol.

Specifically, the IB provides the scientific justification for:

• The proposed dose and dose frequency.
• The route of administration.
• Specific safety monitoring procedures and assessments.
• The clinical management of study subjects.

By reading the IB, an investigator gains insight into the potential risks and adverse drug reactions, as well as the anticipated clinical benefits, allowing for an accurate assessment of the study's risk-benefit ratio.

Structure and Required Contents

The format of the IB is standardized by ICH E6 guidelines to ensure that investigators across the globe can easily navigate the document. A standard IB includes the following sections:

1. Title Page: Includes the sponsor's name, the identity of the IP, the version number, and the release date. It also typically indicates the version number and date of the document it replaces.
2. Confidentiality Statement: The IB is a highly confidential document containing the sponsor's proprietary intellectual property. The sponsor generally requires investigators to keep it secure and not distribute it outside the research team and the IRB/IEC.
3. Table of Contents: For easy navigation.
4. Summary: A brief (usually two pages or less) summary highlighting the significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, and clinical information available.
5. Introduction: Briefly states the chemical name of the IP, all active ingredients, the rationale for performing research with the IP, and the anticipated prophylactic, therapeutic, or diagnostic indications.
6. Physical, Chemical, and Pharmaceutical Properties and Formulation: A description of the IP substance, structural formula, and formulation excipients. This section is vital for understanding proper storage and handling conditions (e.g., light sensitivity, temperature requirements).
7. Nonclinical Studies: This is a comprehensive summary of all relevant nonclinical pharmacology, pharmacokinetics, and toxicology studies (in vitro and in vivo animal models). It details the methodology, results, and relevance of the findings to the proposed human trials. This section highlights target organs for toxicity.
8. Effects in Humans: A detailed discussion of the known effects of the IP in humans. This includes pharmacokinetics, pharmacodynamics, dose response, safety, and efficacy data drawn from previous clinical trials. It also includes information on post-marketing experience if the IP is already approved in other countries or for other indications.
9. Summary of Data and Guidance for the Investigator: This is perhaps the most practical section for the clinical research team. It provides a brief overall summary of all available data and offers direct guidance to the investigator regarding possible risks, adverse reactions, and specific precautions or special monitoring that should be observed during the trial.

Updating the IB

Clinical research is dynamic. As a trial progresses, new data regarding the safety and efficacy of the IP is constantly generated. Therefore, the IB is a living document.

According to ICH GCP, the sponsor is responsible for reviewing the IB at least annually and revising it as necessary in compliance with a sponsor's written procedures.

However, updates must occur more frequently if significant new information becomes available—especially information that impacts subject safety. For example, if a severe, unexpected adverse drug reaction is identified, the sponsor must issue an expedited update to the IB (often accompanied by an urgent safety communication to sites).

When a new version of the IB is released, the CRC must ensure it is promptly submitted to the IRB/IEC for review and acknowledgment. Furthermore, if the new IB identifies new risks, the study's Informed Consent Form (ICF) must typically be revised to inform both new and currently enrolled subjects of these new risks.

The CRC’s Role with the IB

While the Principal Investigator must thoroughly review the IB, the CRC also plays a vital role in managing this document:

• Filing: Ensuring the current approved version, as well as all previous versions, are appropriately filed in the Investigator Site File (ISF) / Regulatory Binder.
• IRB Submissions: Submitting new IB versions to the IRB/IEC in a timely manner according to local institutional policies.
• Safety Reporting: When an adverse event occurs, the investigator uses the IB to determine if the event is "expected" or "unexpected." An unexpected event is one whose nature or severity is not consistent with the applicable product information described in the IB. The CRC assists in ensuring that unexpected serious adverse reactions (SUSARs) are reported per expedited timelines.
• Storage and Handling: Referencing the physical and chemical properties section of the IB (or the associated Pharmacy Manual) to ensure the IP is stored at the correct temperature and prepared correctly.